Theralink Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023
August 21, 2023 at 04:09 pm EDT
Share
Theralink Technologies, Inc. reported earnings results for the third quarter and nine months ended June 30, 2023. For the third quarter, the company reported sales was USD 0.202447 million compared to USD 0.164213 million a year ago. Net income was USD 4.5 million compared to net loss of USD 1.71 million a year ago.
For the nine months, sales was USD 0.427529 million compared to USD 0.262688 million a year ago. Net loss was USD 40.52 million compared to USD 5.06 million a year ago. Basic loss per share from continuing operations was USD 0.01. Diluted loss per share from continuing operations was USD 0.01.
Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.
THERALINK TECHNOLOGIES, INC. 
